Nadofaragene firadenovec, which is a gene-mediated intravesical therapy based on using human IFN-α2b, recorded a CR rate of 53.4% at three months in a phase 3 study conducted with CIS patients—24.3% of them remained free from high-grade relapse after one year [64]. This evidence concerns the gene IFNA2 and in situ carcinoma.